Intervention

BMS-986012

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting0

Common conditions2

Lead sponsors shown1

Clinical trials

3 shown

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerNCT04702880 · 2021-03-17

Study of BMS-986012 in Subjects With Small Cell Lung CanerNCT02949895 · 2016-11-29

Trial of BMS-986012 in Combination With Platinum and EtoposideNCT02815592 · 2016-11-28

Common conditions

Small Cell Lung Cancer2 Extensive-stage Small Cell Lung Cancer1

Leading sponsors

Bristol-Myers Squibb3

Trial status mix

COMPLETED3

Phase mix

PHASE12

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.